He is actively involved in clinical oncology research, with a focus on translating scientific advances into practical, accessible, and patient-centered cancer care.
He has served as the Principal Investigator and First Author of the PLANeT Trial, a randomized phase II clinical trial evaluating low-dose pembrolizumab in combination with neoadjuvant chemotherapy for triple-negative breast cancer, with a particular focus on treatment strategies relevant to resource-constrained settings.
His research interests include:
His research experience encompasses the full clinical research process, including clinical trial design, protocol development, patient recruitment, treatment and response assessment, toxicity monitoring, quality-of-life evaluation, data analysis, and scientific manuscript preparation.
Through clinical research and collaboration, his aim is to contribute to evidence that can improve cancer treatment while making high-quality care more accessible and meaningful to patients.
Dr. Arora has attended and participated in leading oncology academic programs and conferences, including:
Dr. Adhip Arora has published original research articles, clinical trial protocols, conference abstracts, and case reports across oncology and other areas of medicine.
His oncology publications include research related to triple-negative breast cancer, pembrolizumab, neoadjuvant chemotherapy, and health-related quality of life.
Selected publications include research published in:
